Over the past two decades, significant progress in understanding of the pathogenesis of type
2 chronic inflammatory diseases has enabled the identification of compounds for more than …

Chronic rhinosinusitis (CRS) affects up to 12% of the general population and is traditionally
divided into two main phenotypic subsets, based on the presence of nasal polyps …

Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a
significant impact on the quality of life (QoL). It is typically characterized by a type 2 …

Background Several promising clinical trials have demonstrated the effects of type 2
biologics compared with placebos in chronic rhinosinusitis with nasal polyps (CRSwNP) …

Chronic rhinosinusitis with nasal polyps (CRSwNP) associated with type 2 inflammation and
non‐steroidal anti‐inflammatory drug (NSAID)‐exacerbated respiratory disease (N‐ERD) …

Chronic rhinosinusitis (CRS) is an important ENT pathology which affects about 5–12% of
the general population. The treatment of CRS can be pharmacological (nasal sprays …

Background The heterogeneity of existing studies, along with the fact that there are no
published head‐to‐head trials, are the main reasons for the lack of guidelines regarding the …

Siglecs (sialic acid-binding immunoglobulin-like lectins) are a family of vertebrate glycan-
binding cell-surface proteins. The majority mediate cellular inhibitory activity once engaged …

Asthma and nasal polyposis often coexist and are frequently intertwined by tight pathogenic
links, mainly consisting of the cellular and molecular pathways underpinning type 2 airway …

Background Olfactory dysfunction is highly associated with chronic rhinosinusitis with nasal
polyps (CRSwNP), and the severity of loss has been linked with biomarkers of type 2 …